Department of Radiology, The Fourth Hospital of Hebei Medical University, Hebei, China.
Br J Radiol. 2013 Sep;86(1029):20130143. doi: 10.1259/bjr.20130143. Epub 2013 Jul 24.
The purpose of our study was to validate iodine quantification in a phantom study with dual-source dual-energy CT (DECT) and to apply this technique to differentiate benign periablational reactive tissue from residual tumour in VX2 carcinoma in rabbits after radiofrequency ablation (RFA).
We applied iodine quantification with DECT in a phantom and in VX2 carcinoma in rabbits after incomplete RFA to differentiate benign periablational reactive tissue from residual tumour and evaluated its efficacy in demonstrating response to therapeutic RFA. A series of tubes containing solutions of varying iodine concentration were scanned with DECT. The iodine concentration was calculated and compared with known true iodine concentration. Triple-phase contrast-enhanced DECT data on 24 rabbits with VX2 carcinoma were then assessed at Day 3 (n=6), 1 week (n=6), 2 weeks (n=6) and 3 weeks (n=6) after incomplete RFA independently by 2 readers. Dual-energy postprocessing was used to produce iodine-only images. Regions of interest were positioned on the iodine image over the lesion and, as a reference, over the aorta, to record iodine concentration in the lesion and in the aorta. The pathological specimens were sectioned in the same plane as DECT imaging, and the lesion iodine concentration and lesion-to-aorta iodine ratio of residual tumour and benign periablational reactive tissue were assessed.
There was excellent correlation between calculated and true iodine concentration (r=0.999, p<0.0001) in the phantom study. The lesion iodine concentration and lesion-to-aorta iodine ratio in residual tumour were significantly higher than in benign periablational reactive tissue in the 2-week group during the arterial phase (AP) (p<0.01) and in the 3-week group during both the AP (p<0.05) and the portal venous phase (p<0.05). There was no significant difference between them with respect to the lesion iodine concentration or lesion-to-aorta iodine ratio in the 3-day and 1-week groups.
Iodine quantification with DECT is accurate in a phantom study and can be used to differentiate benign periablational reactive tissue from residual tumour in VX2 carcinoma in rabbits after RFA.
Iodine quantification with DECT may help in differentiating benign periablational reactive tissue from residual tumour in VX2 carcinoma in rabbits after RFA.
本研究的目的是验证双源双能 CT(DECT)在体模研究中的碘定量,并将该技术应用于区分兔 VX2 癌射频消融(RFA)后残留肿瘤的良性围消融反应组织。
我们在体模和兔 VX2 癌不完全 RFA 后应用 DECT 进行碘定量,以区分良性围消融反应组织和残留肿瘤,并评估其在显示治疗性 RFA 反应方面的效果。一系列含有不同碘浓度溶液的管在 DECT 下进行扫描。计算碘浓度并与已知的真实碘浓度进行比较。然后,对 24 只兔 VX2 癌患者的三时相增强 DECT 数据进行评估,包括 3 天(n=6)、1 周(n=6)、2 周(n=6)和 3 周(n=6)后,由 2 名读者独立进行双能后处理以生成仅含碘的图像。在碘图像上对病变部位进行感兴趣区域定位,并作为参考在主动脉上进行定位,以记录病变部位和主动脉中的碘浓度。对病变部位的碘浓度和残留肿瘤及良性围消融反应组织的病变与主动脉的碘比值进行评估。
在体模研究中,计算的碘浓度与真实碘浓度之间具有极好的相关性(r=0.999,p<0.0001)。在动脉期(AP)(p<0.01)和门静脉期(p<0.05),2 周组和 3 周组的残留肿瘤中病变的碘浓度和病变与主动脉的碘比值均明显高于良性围消融反应组织。在 3 天和 1 周组,两者之间在病变碘浓度或病变与主动脉的碘比值方面无显著差异。
DECT 碘定量在体模研究中准确可靠,可用于区分兔 VX2 癌 RFA 后残留肿瘤的良性围消融反应组织。
DECT 碘定量有助于区分兔 VX2 癌 RFA 后残留肿瘤的良性围消融反应组织。